Dasiglucagon Hydrochloride Patent Expiration
Dasiglucagon Hydrochloride is Used for managing low blood sugar levels in diabetic patients. It was first introduced by Zealand Pharma Us Inc
Dasiglucagon Hydrochloride Patents
Given below is the list of patents protecting Dasiglucagon Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Zegalogue | US10442847 | Glucagon analogues | Feb 03, 2035 | Zealand Pharma |
| Zegalogue (autoinjector) | US10442847 | Glucagon analogues | Feb 03, 2035 | Zealand Pharma |
| Zegalogue | US11795204 | Glucagon analogues | Jan 06, 2034 | Zealand Pharma |
| Zegalogue (autoinjector) | US11795204 | Glucagon analogues | Jan 06, 2034 | Zealand Pharma |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Dasiglucagon Hydrochloride's patents.
Latest Legal Activities on Dasiglucagon Hydrochloride's Patents
Given below is the list recent legal activities going on the following patents of Dasiglucagon Hydrochloride.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Mail Patent eCofC Notification | 25 Jun, 2024 | US11795204 |
| Email Notification Critical | 25 Jun, 2024 | US11795204 |
| Patent eCofC Notification | 25 Jun, 2024 | US11795204 |
| Recordation of Patent eCertificate of Correction | 25 Jun, 2024 | US11795204 |
| Post Issue Communication - Certificate of Correction | 05 Jun, 2024 | US11795204 |
| transaction for FDA Determination of Regulatory Review Period | 30 Nov, 2023 | US10442847 |
| Email Notification Critical | 24 Oct, 2023 | US11795204 |
| Patent Issue Date Used in PTA Calculation Critical | 24 Oct, 2023 | US11795204 |
| Mail Patent eGrant Notification | 24 Oct, 2023 | US11795204 |
| Recordation of Patent eGrant | 24 Oct, 2023 | US11795204 |
Dasiglucagon Hydrochloride's Family Patents
